

Friday August 29, 2025



2025 Interim Results Earnings Call

Dear Investors:

Hua Medicine (2552.HK) cordially invites you or your representative to attend the conference call for the Company's 2025 Interim results, which will be held 8:00 AM HKT, August 29, 2025 (Friday).

During the conference call, management will provide a review of the Company's first half year financial results in 2025, business updates, as well as address plans for the future.

Details of the earnings call are as follows:

Date:	August 29, 2025
Time:	Login starts: 7:45AM HKT Meeting starts: 8:00AM HKT
Duration:	Approximately 60mins (including Q&A session)
Language:	English
Management:	Dr. Li Chen, Founder and CEO Mr. George Lin, EVP & Chief Strategy Officer
RSVP:	Webinar Link : https://cls.a.zoom.com/join/91234567890 *Please input your personal particulars and you will be directed to the page with connection details of this webinar.

About Hua Medicine

Hua Medicine (The "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁®) (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing (华堂宁®) was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.